Effect of D-cycloserine on Treatment of Posttraumatic Stress Disorder (PTSD) in Youth
NCT ID: NCT01157416
Last Updated: 2017-04-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
33 participants
INTERVENTIONAL
2010-06-30
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents
NCT01157429
Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD
NCT03216356
RCT of CBT Combined With D-Cycloserine for Treating PTSD
NCT00452231
The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear Healthy Controls.
NCT01733030
Imaginal Exposure & D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)
NCT00875342
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
D-cycloserine (DCS), an antibiotic that has been used for over 50 years, has also been found to have positive effects on cognition and anxiety. DCS was found to enhance learning and memory, and also facilitates extinction of fear reactions. However, DCS only produces an extinction effect when paired with behavioral training, not when simply given alone. Thus, the medication only needs to be given for seven doses in this research and youth do not need to take the medication long term. The research also includes a three-month follow-up assessment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
D-cycloserine plus CBT
Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
D-cycloserine
D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
CBT
12-session CBT protocol, called Youth PTSD Treatment.
Placebo plus CBT
Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
Placebo pill
Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
CBT
12-session CBT protocol, called Youth PTSD Treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-cycloserine
D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
Placebo pill
Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
CBT
12-session CBT protocol, called Youth PTSD Treatment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be able to swallow pills
Exclusion Criteria
* Epilepsy
* Bipolar
* Psychosis
7 Years
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
Tulane University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael S. Scheeringa
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael S Scheeringa, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Tulane University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tulane University Health Sciences Center, 1440 Canal St.
New Orleans, Louisiana, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Scheeringa MS, Lilly ME, Staiger AB, Heller ML, Jones EG, Weems CF. Do Children and Adolescents Have Different Types of Trauma Narratives and Does It Matter? Reliability and Face Validation for a Narrative Taxonomy. J Trauma Stress. 2017 Jun;30(3):323-327. doi: 10.1002/jts.22190. Epub 2017 Jun 1.
Scheeringa MS, Weems CF. Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress. J Child Adolesc Psychopharmacol. 2014 Mar;24(2):69-77. doi: 10.1089/cap.2013.0106. Epub 2014 Feb 7.
Other Identifiers
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.